Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study
At the time Visterra made a bid early this year to go public, the timing was off. The boom of 2014 was long gone and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
